Remdesivir for the Treatment of Upper Respiratory Tract Infection Due to RSV in Immunocompromised Individuals

Part of paid clinical trials in Duarte, California.

Sponsor
Fred Hutchinson Cancer Center
Study ID
NCT06817889
Phase
PHASE2
Status
Recruiting
Apply to this trial

Conditions

  • Autoimmune Disease
  • Hematopoietic and Lymphatic System Neoplasm
  • Respiratory Syncytial Virus Infection

Eligibility Criteria

Sex
ALL
Age
18 Years - N/A
Healthy Volunteers
Not accepted

Interventions

  • Remdesivir — DRUG
    Given IV
  • Survey Administration — OTHER
    Ancillary studies
  • Biospecimen Collection — PROCEDURE
    Undergo blood sample collection
  • Nasal Swab — PROCEDURE
    Undergo nasal swabs

Study Details

This phase II trial tests how well remdesivir works for treatment of respiratory syncytial virus (RSV) infection of the upper respiratory tract in patients receiving cellular or bispecific antibody therapy. Cellular or bispecific antibody therapies cause suppression of the immune system, making infections more frequent and reducing the body's ability to fight the infections. RSV infections are one of the most common respiratory infections in immunocompromised individuals and can cause significant pneumonia and even death. Remdesivir is in a class of medications called antivirals. It works by stopping viruses from spreading in the body.

Key Dates

Start date
Dec 23, 2025
Status verified
Jun 2026
Primary completion
Nov 30, 2027
Completion
Nov 30, 2027

Study Design

Enrollment
60 participants (estimated)
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT

Arms

  • Experimental: Treatment (remdesivir)
    Patients receive remdesivir IV over 30-120 minutes on days 1-5, with the option to extend to day 10 at the investigator's discretion, in the absence of disease progression or unacceptable toxicity. Patients also undergo nasal swabs and blood sample collection throughout the study.

Primary Outcome Measure

Proportion of participants requiring ≥ 2 liters/minute of oxygen for ≥ 24 consecutive hours [ Time Frame: Up to day 29 ]

Central Contacts

Locations (3)

FacilityCityStateZIPSite coordinators
City of Hope Comprehensive Cancer CenterDuarteCalifornia91010
Sanjeet Dadwal, MD (PRINCIPAL_INVESTIGATOR)
MD Anderson Cancer CenterHoustonTexas77030
Fareed Khawaja, MBBS (PRINCIPAL_INVESTIGATOR)
Fred Hutch/University of Washington Cancer ConsortiumSeattleWashington98109
Joshua Hill, MD
[email protected]
206-667-6504
Joshua Hill, MD (PRINCIPAL_INVESTIGATOR)

Find similar trials in Duarte, CA

By research site
City of Hope Comprehensive Cancer Center· Duarte, CAMD Anderson Cancer Center· Houston, TXFred Hutch/University of Washington Cancer Consortium· Seattle, WA

Related Studies